Sun Pharma keeps Organon Q4 FY27 close on track, costs continue
Key highlights
- Sun Pharma said the Organon acquisition is on track to close in Q4 FY27.
- Regulatory approvals are secured in a majority of regions, with the remaining jurisdiction on schedule.
- Organon-related acquisition costs will continue until day 1 and may be back-ended.
- Sun Pharma reported Q2 FY27 sales of Rs 16,100 crore, up 11.8% year on year.
powered by IRIS

Sun Pharmaceutical Industries Limited, referred to as Sun Pharma, said on October 30, 2026, that its Organon acquisition remains on track to close in Q4 FY27 after regulatory approvals were secured in a majority of regions, while acquisition-related exceptional costs will continue until the transaction closes. The remaining jurisdiction is progressing on schedule, management said.
Know Sun Pharmaceutical Industries inside out
Results, valuation, peers and who's buying, in one view.
Is Sun Pharma still on track to complete the Organon acquisition?
Yes, Sun Pharma said the Organon acquisition remains on track to close in Q4 FY27, its previously communicated timetable. Management said integration planning is advancing across functions and work streams, while the deal remains subject to the remaining customary closing conditions. The company had also described the target as an early-2027 close in its October 30 call introduction.
The stated progress is regulatory rather than a completed transaction. Sun Pharma said approvals have been secured in a majority of regions, and the remaining jurisdiction is tracking to schedule. Management did not disclose the number of regions, the jurisdiction still pending or the precise date within Q4 FY27.
Sun Pharma did not discuss Organon’s operating performance because Organon remains a separately listed public company. That distinction limits the update to closing conditions and integration planning rather than Organon sales, profitability, product performance or its financial contribution after consolidation.
What Organon acquisition costs will Sun Pharma record before closing?
Sun Pharma expects acquisition-related costs to continue until day 1, and said some costs could be back-ended as the transaction approaches a Q4 FY27 closing. Chief Financial Officer Jayashree Satagopan said the company would have a full estimate of acquisition-related costs when the transaction closes, rather than providing a forecast during the Q2 FY27 call.
The company already included Organon-related acquisition costs within exceptional items in Q2 FY27. Those exceptional items also included a provision for a litigation settlement, so the call did not disclose a standalone rupee figure for Organon costs. Sun Pharma reported Q2 FY27 net profit after tax of Rs 1,988.5 crore and adjusted net profit of Rs 3,162 crore, showing the gap between reported and adjusted earnings during the quarter.
Management said further transaction expenses are normal for a transaction of this size. That is management’s view rather than quantified guidance: the transcript gives neither a total acquisition-cost estimate nor a breakdown among advisory, financing, integration, legal and other Q4 FY27 closing expenses.
Got a follow-up? Ask IRIS
How does the pending deal sit alongside Sun Pharma’s Q2 FY27 results?
Sun Pharma reported Q2 FY27 consolidated sales of Rs 16,100 crore, up 11.8% from Q2 FY26, while earnings before interest, tax, depreciation and amortisation rose 4.8% to Rs 4,743.9 crore. Revenue therefore increased faster than operating profit, with management noting that Q2 FY26 had benefited from lenalidomide sales.
The company said Q2 FY27 gross margin was 80.8%, higher than a year earlier because of product mix and favourable currency tailwinds, while the earnings before interest, tax, depreciation and amortisation margin was 29.3%. Management added that, adjusted for lenalidomide, operating-profit growth exceeded revenue growth. The Organon deal costs were classified as exceptional items rather than disclosed as recurring operating expenses.
For the first half of FY27, Sun Pharma recorded sales of Rs 31,283.6 crore, up 11%, and earnings before interest, tax, depreciation and amortisation of Rs 9,161.6 crore, up 3.8%. Adjusted first-half net profit was Rs 6,251.5 crore. These figures cover Sun Pharma’s existing operations, as the company gave no pro forma results combining Sun Pharma and Organon.
What financing and accounting details remain unresolved for Organon?
Sun Pharma said its expected borrowing rate for the acquisition should be broadly in line with Organon’s current weighted average cost of debt. Management did not state a percentage, debt amount, maturity profile or final financing mix during the October 30, 2026 call, so the final interest-cost effect cannot be calculated from the transcript.
The company also said goodwill will be determined through applicable accounting standards at the acquisition date. Management therefore declined to estimate what portion of the purchase consideration could be allocated to goodwill before Q4 FY27 closing. This leaves the final acquisition accounting and full acquisition-related cost estimate unresolved.
Sun Pharma distinguished its recent non-convertible debenture issue from transaction financing in the Q2 FY27 discussion. Management said the rupee-denominated debentures were issued as part of normal financing to repay existing borrowings, while Organon financing is expected to be mostly in US dollars and euros. The debenture borrowing rate is therefore not a like-for-like indicator of the Organon transaction’s financing cost.
Conclusion
Sun Pharma has moved the Organon transaction through approvals in a majority of regions and into final integration preparation, while its Q2 FY27 results showed 11.8% sales growth to Rs 16,100 crore. The difference between reported net profit of Rs 1,988.5 crore and adjusted net profit of Rs 3,162 crore also provides context for exceptional items that included acquisition-related costs and a litigation-settlement provision.
The next item to watch is Q4 FY27, when management expects the transaction to close and provide a full estimate of acquisition-related costs. The remaining jurisdiction, customary closing conditions, acquisition-date goodwill assessment and final financing structure are the disclosed matters still to be resolved.


